Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Revolutionary ovarian cancer rapid test available Q4 2022
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The plant is expected to start commercial operations from Q4FY24
Subscribe To Our Newsletter & Stay Updated
